Skip to main content
. Author manuscript; available in PMC: 2017 Jan 1.
Published in final edited form as: Cancer Lett. 2015 Oct 22;370(1):78–84. doi: 10.1016/j.canlet.2015.09.020

Table 1.

Brief summary of current clinical modalities for the treatment of HCCs [3–7].

Modalities Status Indication 5-year OS (%)
HR Best treatment for non-cirrhosis patients. BCLC stage 0/A 37–53
LT Best treatment for cirrhotic patients. BCLC stage 0/A 38.2–46.5
RFA Comparable to HR in small HCCs. BCLC stage 0/A 33–60.2
TACE Standard of care for patients with large or multi-nodular HCC. BCLC stage B 26–34
Sorafenib The only approved systemic therapy. BCLC stage C 2–3 month OS prolongation

HR = hepatic resection; LT = liver transplantation; RFA = radiofrequency ablation; TACE = transhepatic arterial chemoembolization; OS = overall survival; BCLC = Barcelona Clinic Liver Cancer.